EP3310810
PD-L1 ANTAGONIST COMBINATION TREATMENTS
Status:
EP einkaleyfi: EP einkaleyfi tilnefnt til gildistöku á ÍslandiEP appl. date:
15.6.2016EP published:
1.4.2026EP application number:
16732440.9
EPO information:
European Patent Register
Max expiry date:
14.6.2036Expiry date:
31.7.2026
Title in English:
PD-L1 ANTAGONIST COMBINATION TREATMENTSLanguage of the patent:
English
Timeline
Today
15.6.2016EP application
1.4.2026EP Publication
31.7.2026Expires
Owner
Name:
Merck Patent GmbHAddress:
Frankfurter Strasse 250, 64293 Darmstadt, DE
Name:
Pfizer Inc.Address:
235 East 42nd Street, New York, NY 10017, US
Inventor
Name:
ANDREWS, Glen IanAddress:
San Diego, California 92127, US
Name:
CHEN, ShihaoAddress:
Foster City, California 94404, US
Name:
DI PIETRO, AlessandraAddress:
20090 Opera, IT
Name:
FONTANA, DavidAddress:
Clyde Hill, Washington 98004, US
Name:
GOLDBERG, ZelannaAddress:
San Diego, CA 92122, US
Name:
LIN, Chia-YangAddress:
Scarsdale, NY 10583, US
Name:
LONG, HuaAddress:
San Carlos, CA 94070, US
Name:
MARTIGNONI, MarcellaAddress:
Parabiago Milan, IT
Name:
NUYTEN, Dimitry Serge AntoineAddress:
San Francisco, California 94111, US
Name:
THALL, Aron DavidAddress:
San Diego, California 92130, US
Name:
WOOLFSON, AdrianAddress:
New York, New York 10017, US
Priority
Number:
201562180543 PDate:
16.6.2015Country:
US
Number:
201562219995 PDate:
17.9.2015Country:
US
Number:
201662286501 PDate:
25.1.2016Country:
US
Number:
201662337489 PDate:
17.5.2016Country:
US
Classification
Categories:
C07K 16/24, C07K 16/28, A61P 35/00, A61K 31/4439, A61K 39/00